Two-years Results From PANORAMA Trial of Aflibercept for Nonproliferative Diabetic Retinopathy Presented at ARVO
Patients with moderately severe to severe nonproliferative diabetic retinopathy fared better with intravitreal aflibercept injection compared to sham, according to 2-year results of the PANORAMA study presented at Association for Research in Vision and Ophthalmology virtual meeting.
The study included 402 patients with nonproliferative diabetic retinopathy without diabetic macular edema randomized to receive intravitreal aflibercept 2 mg every 16 weeks after 3 monthly doses or every 8 weeks after 5 monthly doses, or sham.
At week 52, 65% of eyes treated every 16-weeks and 80% of eyes treated every 8-weeks had a ≥2-step improvement in DRSS score versus 15% of eyes in the sham group. A ≥3-step improvement in DRSS score was seen in 9%, 15%, and <1% of eyes treated every 16-weeks, every 8-weeks, and with sham.
At week 100, the same level was achieved by 62% of patients in the 16-week arm and 50% of patients in the 8-week arm, compared with 13% of patients in the sham group.
Patients treated with intravitreal aflibercept were less likely to develop a vision-threatening complication or diabetic macular edema compared with those in the sham group.
Lim JI. Intravitreal aflibercept injection for nonproliferative diabetic retinopathy: Year 2 results from the PANORAMA study. Presented at: Association for Research in Vision and Ophthalmology virtual meeting; May 6, 2020.